Cabazitaxel: a novel second-line treatment for metastatic castration-resistant prostate cancer

Until recently, patients with castration-resistant prostate cancer (CRPC) had limited therapeutic options once they became refractory to docetaxel chemotherapy, and no treatments improved survival. This changed in June 2010 when the Food and Drug Administration (FDA) approved cabazitaxel as a new op...

Descripción completa

Detalles Bibliográficos
Autores principales: Paller, Channing J, Antonarakis, Emmanuel S
Formato: Texto
Lenguaje:English
Publicado: Dove Medical Press 2011
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3063116/
https://www.ncbi.nlm.nih.gov/pubmed/21448449
http://dx.doi.org/10.2147/DDDT.S13029

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3063116/
https://www.ncbi.nlm.nih.gov/pubmed/21448449
http://dx.doi.org/10.2147/DDDT.S13029

Ejemplares similares